Why Repros Is Poised to Keep Plunging

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage biotech company Repros Therapeutics (NASDAQ: RPRX  ) has received the dreaded one-star ranking.

With that in mind, let's take a closer look at Repros and see what CAPS investors are saying about the stock right now.

Repros facts

Headquarters (founded)

The Woodlands, Texas (1987)

Market Cap

$208.1 million

Industry

Pharmaceuticals

Trailing-12-Month EBITDA

($12.7 million)

Management

CEO Joseph Podolski (since 1992)
CFO Katherine Anderson (since 2011)

Trailing-12-Month Return on Equity

(69.9%)

Cash/Debt

$29.6 million / $0

Competitors

Abbott Labs
Auxilium Pharmaceuticals
Actavis

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 54% of the 131 members who have rated Repros believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star TerryHogan, succinctly summed up the Repros bear case for our community:

They're burning through cash like a former child-star on a [V]egas bender, and they're handing out shares like they're breath mints at a halitosis convention. They have no revenues to speak of (in fact they don't have any revenue at all). And while the latest announcement about their clinical trial isn't exactly a nail in the coffin, it could be a sign of greater malfeasance.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 07, 2013, at 12:35 PM, tjsimone wrote:

    So, you write an article, based off another Fools opinion, with the headline "Why Repros Is Poised to Keep Plunging "....

    I must say, the article is chock full of indepth analysis to back your headline...

    Whats say you of the Wall Street vote of 2-0 that it will outperform?

    Disclosure...I dont own, but was looking to gain maybe just a little insight....what a waste of 10 minutes of my life...

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2234263, ~/Articles/ArticleHandler.aspx, 12/17/2014 7:46:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement